Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 9/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27620720 | 1.00 | LMNA (0.48) | LMNAPOLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3044863 | 0.90 | LMNA (0.37) | LMNAPOLBSMN1; SMN2F10 | |
| SCHEMBL3036010 | 0.88 | MAOA (0.46) | LMNAPOLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3038512 | 0.88 | LMNA (0.43) | LMNAPOLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5998091 | 0.84 | F10 (0.41) | LMNAPOLBF10ALDH1A1 | |
| SCHEMBL3039865 | 0.83 | F10 (0.40) | F10PDE3BPDE3A | |
| SCHEMBL27620718 | 0.81 | LMNA (0.46) | LMNAPOLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL27602103 | 0.80 | MAOA (0.34) | LMNAF10 | |
| SCHEMBL3029185 | 0.80 | F10 (0.56) | LMNAF10PDE3BPDE3AL3MBTL1 | |
| SCHEMBL27602094 | 0.80 | F10 (0.56) | LMNAF10PDE3BPDE3AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1478629-B1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN CO LLC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1478629-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | LMNA 3385/4885POLB 1744/4885SMN1; SMN2 2043/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | LMNA 3385/4885POLB 1744/4885SMN1; SMN2 2043/4885 |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | LMNA 3385/4885POLB 1744/4885SMN1; SMN2 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.